



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration
Rockville, MD 20857

NDA 50-536/S-016

F. H. Faulding & Co. Limited
c/o Warner Chilcott, Inc.
Attention: Deepa Desai
Manager, Regulatory Affairs
Rockaway 80 Corporate Center
100 Enterprise Drive, Suite 280
Rockaway, NJ 07866

Dear Ms. Desai:

Please refer to your supplemental new drug application dated February 27, 2003, received February 28, 2003, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Eryc[®] (erythromycin delayed-release) Capsules.

This application is subject to the exemption provisions contained in section 125(d)(2) of Title I of the FDA Modernization Act of 1997.

This supplemental new drug application provides for revised labeling in response to the FDA letter dated June 9, 2000, to all holders of approved NDAs for fluoroquinolone and macrolide antimicrobial agents.

We have completed our review of this application and it is approved effective on the date of this letter.

We also remind you to submit a supplement that addresses the Geriatric Use subsection of the label to comply with the Final Rule published on August 27, 1997, titled "Specific Requirements on Content and Format of Labeling for Human Prescriptions Drugs: Addition of "Geriatric Use" Subsection in the Labeling."

The final printed labeling (FPL) must be identical to the package insert submitted February 27, 2003.

Please submit the FPL electronically according to the guidance for industry titled Providing Regulatory Submissions in Electronic Format – NDA. Alternatively, you may submit 20 paper copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount 15 of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 50-536/S-016." Approval of this submission by FDA is not required before the labeling is used.

If you issue a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter), we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HFD-410
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).

If you have any questions, call Judit Milstein, Regulatory Project Manager, at (301) 827-2207.

Sincerely,

{See appended electronic signature page}

Janice M. Soreth, MD
Director
Division of Anti-Infective Drug Products
Office of Drug Evaluation IV
Center for Drug Evaluation and Research

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Janice Soreth

2/2/04 04:59:37 PM